Medical - Healthcare Information Services
Build Your Comparison
Side-by-side financial analysisStock Comparison
FORA vs INFU vs HCAT vs CSGP vs VRNT vs KO
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Healthcare Information Services
Real Estate - Services
Software - Infrastructure
Beverages - Non-Alcoholic
FORA vs INFU vs HCAT vs CSGP vs VRNT vs KO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||||
|---|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Instruments & Supplies | Medical - Healthcare Information Services | Real Estate - Services | Software - Infrastructure | Beverages - Non-Alcoholic |
| Market Cap | $68M | $190M | $129M | $12.77B | $1.24B | $341.71B |
| Revenue (TTM) | $30M | $142M | $302M | $3.41B | $894M | $49.28B |
| Net Income (TTM) | $-5M | $8M | $-265M | $25M | $61M | $13.70B |
| Gross Margin | 46.8% | 56.7% | 46.0% | 77.4% | 69.9% | 61.7% |
| Operating Margin | -13.4% | 9.1% | -19.2% | -0.8% | 8.6% | 29.3% |
| Forward P/E | — | 22.2x | 44.8x | 22.1x | 7.0x | 24.3x |
| Total Debt | $12K | $3M | $171M | $1.14B | $448M | $45.49B |
| Cash & Equiv. | $13M | $3M | $51M | $1.73B | $216M | $10.27B |
FORA vs INFU vs HCAT vs CSGP vs VRNT vs KO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Forian Inc. (FORA) | 100 | 21.5 | -78.5% |
| InfuSystem Holdings… (INFU) | 100 | 49.8 | -50.2% |
| Health Catalyst, In… (HCAT) | 100 | 2.7 | -97.3% |
| CoStar Group, Inc. (CSGP) | 100 | 42.1 | -57.9% |
| Verint Systems Inc. (VRNT) | 100 | 44.6 | -55.4% |
| The Coca-Cola Compa… (KO) | 100 | 149.4 | +49.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FORA vs INFU vs HCAT vs CSGP vs VRNT vs KO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
FORA is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 50.1%, EPS growth 23.0%, 3Y rev CAGR 22.6%
- Lower volatility, beta 0.21, Low D/E 0.0%, current ratio 2.97x
- Beta 0.21, current ratio 2.97x
- 50.1% revenue growth vs VRNT's -0.1%
INFU ranks third and is worth considering specifically for long-term compounding.
- 240.1% 10Y total return vs KO's 115.0%
- +52.2% vs CSGP's -62.1%
Among these 6 stocks, HCAT doesn't own a clear edge in any measured category.
CSGP doesn't hold a clear category lead here; it's more of a secondary option in this specific comparison.
VRNT is the clearest fit if your priority is valuation efficiency.
- PEG 0.36 vs KO's 2.17
- Lower P/E (7.0x vs 24.3x), PEG 0.36 vs 2.17
KO carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 56 yrs, beta -0.23, yield 2.6%
- 27.8% margin vs HCAT's -87.7%
- 2.6% yield, 56-year raise streak, vs VRNT's 1.6%, (4 stocks pay no dividend)
- 13.1% ROA vs HCAT's -50.1%, ROIC 15.8% vs -6.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 50.1% revenue growth vs VRNT's -0.1% | |
| Value | Lower P/E (7.0x vs 24.3x), PEG 0.36 vs 2.17 | |
| Quality / Margins | 27.8% margin vs HCAT's -87.7% | |
| Stability / Safety | Beta 0.21 vs HCAT's 1.63, lower leverage | |
| Dividends | 2.6% yield, 56-year raise streak, vs VRNT's 1.6%, (4 stocks pay no dividend) | |
| Momentum (1Y) | +52.2% vs CSGP's -62.1% | |
| Efficiency (ROA) | 13.1% ROA vs HCAT's -50.1%, ROIC 15.8% vs -6.1% |
FORA vs INFU vs HCAT vs CSGP vs VRNT vs KO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FORA vs INFU vs HCAT vs CSGP vs VRNT vs KO — Financial Metrics
Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
KO leads in 5 of 6 categories
FORA leads 0 • INFU leads 0 • HCAT leads 0 • CSGP leads 0 • VRNT leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
KO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
KO is the larger business by revenue, generating $49.3B annually — 1640.0x FORA's $30M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to HCAT's -87.7%. On growth, CSGP holds the edge at +22.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| RevenueTrailing 12 months | $30M | $142M | $302M | $3.4B | $894M | $49.3B |
| EBITDAEarnings before interest/tax | -$4M | $26M | -$8M | $278M | $127M | $15.5B |
| Net IncomeAfter-tax profit | -$5M | $8M | -$265M | $25M | $61M | $13.7B |
| Free Cash FlowCash after capex | $2M | $20M | $9M | $241M | $118M | $12.6B |
| Gross MarginGross profit ÷ Revenue | +46.8% | +56.7% | +46.0% | +77.4% | +69.9% | +61.7% |
| Operating MarginEBIT ÷ Revenue | -13.4% | +9.1% | -19.2% | -0.8% | +8.6% | +29.3% |
| Net MarginNet income ÷ Revenue | -17.0% | +5.6% | -87.7% | +0.7% | +6.9% | +27.8% |
| FCF MarginFCF ÷ Revenue | +7.8% | +14.3% | +3.0% | +7.1% | +13.2% | +25.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.9% | -3.0% | -10.9% | +22.5% | -1.0% | +12.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.0% | +5.9% | -3.4% | +127.7% | -5.1% | +18.2% |
Valuation Metrics
Evenly matched — INFU and HCAT and VRNT each lead in 2 of 7 comparable metrics.
Valuation Metrics
At 19.7x trailing earnings, VRNT trades at a 99% valuation discount to CSGP's 1814.5x P/E. Adjusting for growth (PEG ratio), VRNT offers better value at 1.02x vs KO's 2.34x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Market CapShares × price | $68M | $190M | $129M | $12.8B | $1.2B | $341.7B |
| Enterprise ValueMkt cap + debt − cash | $55M | $190M | $249M | $12.2B | $1.5B | $376.9B |
| Trailing P/EPrice ÷ TTM EPS | -23.48x | 30.39x | -0.68x | 1814.46x | 19.72x | 26.12x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 22.16x | 44.85x | 22.11x | 7.00x | 24.27x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 1.02x | 2.34x |
| EV / EBITDAEnterprise value multiple | — | 7.55x | 17.30x | 71.63x | 9.46x | 25.45x |
| Price / SalesMarket cap ÷ Revenue | 2.24x | 1.33x | 0.41x | 3.93x | 1.37x | 7.13x |
| Price / BookPrice ÷ Book value/share | 2.27x | 3.47x | 0.49x | 1.52x | 0.97x | 9.99x |
| Price / FCFMarket cap ÷ FCF | 23.49x | 7.97x | — | 311.35x | 8.75x | 64.52x |
Profitability & Efficiency
KO leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-100 for HCAT. FORA carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), INFU scores 8/9 vs CSGP's 5/9, reflecting strong financial health.
| Metric | ||||||
|---|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -17.2% | +14.0% | -99.8% | +0.3% | +4.6% | +41.1% |
| ROA (TTM)Return on assets | -11.8% | +7.9% | -50.1% | +0.2% | +2.8% | +13.1% |
| ROICReturn on invested capital | -7.5% | +12.5% | -6.1% | -0.9% | +5.3% | +15.8% |
| ROCEReturn on capital employed | -8.2% | +14.3% | -7.6% | -0.8% | +5.9% | +17.3% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 8 | 5 | 5 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.00x | 0.06x | 0.70x | 0.14x | 0.34x | 1.33x |
| Net DebtTotal debt minus cash | -$13M | $241,000 | $120M | -$589M | $233M | $35.2B |
| Cash & Equiv.Liquid assets | $13M | $3M | $51M | $1.7B | $216M | $10.3B |
| Total DebtShort + long-term debt | $12,137 | $3M | $171M | $1.1B | $448M | $45.5B |
| Interest CoverageEBIT ÷ Interest expense | -48.78x | 15.54x | -6.62x | 1.58x | 8.24x | 10.70x |
Total Returns (Dividends Reinvested)
KO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KO five years ago would be worth $16,528 today (with dividends reinvested), compared to $319 for HCAT. Over the past 12 months, INFU leads with a +52.2% total return vs CSGP's -62.1%. The 3-year compound annual growth rate (CAGR) favors KO at 11.7% vs HCAT's -48.0% — a key indicator of consistent wealth creation.
| Metric | ||||||
|---|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +2.4% | +12.3% | -23.7% | -54.1% | — | +16.4% |
| 1-Year ReturnPast 12 months | +2.4% | +52.2% | -52.3% | -62.1% | +24.8% | +17.7% |
| 3-Year ReturnCumulative with dividends | -7.3% | -7.6% | -85.9% | -64.7% | -44.1% | +39.3% |
| 5-Year ReturnCumulative with dividends | -82.7% | -50.2% | -96.8% | -65.7% | -54.4% | +65.3% |
| 10-Year ReturnCumulative with dividends | -90.5% | +240.1% | -95.6% | +43.4% | -41.6% | +115.0% |
| CAGR (3Y)Annualised 3-year return | -2.5% | -2.6% | -48.0% | -29.3% | -17.6% | +11.7% |
Risk & Volatility
KO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.23 beta — it tends to amplify market swings less than HCAT's 1.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 94.5% from its 52-week high vs CSGP's 30.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.21x | 1.22x | 1.63x | 0.45x | 1.02x | -0.23x |
| 52-Week HighHighest price in past year | $2.71 | $11.04 | $4.13 | $97.43 | $22.84 | $84.04 |
| 52-Week LowLowest price in past year | $1.64 | $5.38 | $0.96 | $29.53 | $16.23 | $65.35 |
| % of 52W HighCurrent price vs 52-week peak | +80.1% | +85.3% | +42.1% | +30.9% | +89.8% | +94.5% |
| RSI (14)Momentum oscillator 0–100 | 63.8 | 41.5 | 59.5 | 31.0 | 68.4 | 49.2 |
| Avg Volume (50D)Average daily shares traded | 40K | 172K | 1.4M | 7.0M | 0 | 13.6M |
Analyst Outlook
KO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: INFU as "Buy", HCAT as "Buy", CSGP as "Buy", VRNT as "Hold", KO as "Buy". Consensus price targets imply 103.1% upside for CSGP (target: $61) vs 8.5% for KO (target: $86). For income investors, KO offers the higher dividend yield at 2.56% vs VRNT's 1.56%.
| Metric | ||||||
|---|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | — | $15.00 | $2.25 | $61.18 | $32.57 | $86.13 |
| # AnalystsCovering analysts | — | 3 | 22 | 25 | 16 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +1.6% | +2.6% |
| Dividend StreakConsecutive years of raises | — | — | — | — | 0 | 56 |
| Dividend / ShareAnnual DPS | — | — | — | — | $0.32 | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +5.8% | +3.9% | +4.5% | +5.8% | +0.2% |
KO leads in 5 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
FORA vs INFU vs HCAT vs CSGP vs VRNT vs KO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is FORA or INFU or HCAT or CSGP or VRNT or KO a better buy right now?
For growth investors, Forian Inc.
(FORA) is the stronger pick with 50. 1% revenue growth year-over-year, versus -0. 1% for Verint Systems Inc. (VRNT). Verint Systems Inc. (VRNT) offers the better valuation at 19. 7x trailing P/E (7. 0x forward), making it the more compelling value choice. Analysts rate InfuSystem Holdings, Inc. (INFU) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — FORA or INFU or HCAT or CSGP or VRNT or KO?
On trailing P/E, Verint Systems Inc.
(VRNT) is the cheapest at 19. 7x versus CoStar Group, Inc. at 1814. 5x. On forward P/E, Verint Systems Inc. is actually cheaper at 7. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Verint Systems Inc. wins at 0. 36x versus The Coca-Cola Company's 2. 17x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — FORA or INFU or HCAT or CSGP or VRNT or KO?
Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.
3%, compared to -96. 8% for Health Catalyst, Inc. (HCAT). Over 10 years, the gap is even starker: INFU returned +240. 1% versus HCAT's -95. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — FORA or INFU or HCAT or CSGP or VRNT or KO?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
23β versus Health Catalyst, Inc. 's 1. 63β — meaning HCAT is approximately -796% more volatile than KO relative to the S&P 500. On balance sheet safety, Forian Inc. (FORA) carries a lower debt/equity ratio of 0% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.
05Which is growing faster — FORA or INFU or HCAT or CSGP or VRNT or KO?
By revenue growth (latest reported year), Forian Inc.
(FORA) is pulling ahead at 50. 1% versus -0. 1% for Verint Systems Inc. (VRNT). On earnings-per-share growth, the picture is similar: Verint Systems Inc. grew EPS 271. 4% year-over-year, compared to -121. 7% for Health Catalyst, Inc.. Over a 3-year CAGR, FORA leads at 22. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — FORA or INFU or HCAT or CSGP or VRNT or KO?
The Coca-Cola Company (KO) is the more profitable company, earning 27.
3% net margin versus -57. 2% for Health Catalyst, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -11. 6% for HCAT. At the gross margin level — before operating expenses — CSGP leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is FORA or INFU or HCAT or CSGP or VRNT or KO more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Verint Systems Inc. (VRNT) is the more undervalued stock at a PEG of 0. 36x versus The Coca-Cola Company's 2. 17x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Verint Systems Inc. (VRNT) trades at 7. 0x forward P/E versus 44. 8x for Health Catalyst, Inc. — 37. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CSGP: 103. 1% to $61. 18.
08Which pays a better dividend — FORA or INFU or HCAT or CSGP or VRNT or KO?
In this comparison, KO (2.
6% yield), VRNT (1. 6% yield) pay a dividend. FORA, INFU, HCAT, CSGP do not pay a meaningful dividend and should not be held primarily for income.
09Is FORA or INFU or HCAT or CSGP or VRNT or KO better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
23), 2. 6% yield, +115. 0% 10Y return). Health Catalyst, Inc. (HCAT) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +115. 0%, HCAT: -95. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between FORA and INFU and HCAT and CSGP and VRNT and KO?
These companies operate in different sectors (FORA (Healthcare) and INFU (Healthcare) and HCAT (Healthcare) and CSGP (Real Estate) and VRNT (Technology) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: FORA is a small-cap high-growth stock; INFU is a small-cap quality compounder stock; HCAT is a small-cap quality compounder stock; CSGP is a mid-cap high-growth stock; VRNT is a small-cap quality compounder stock; KO is a large-cap quality compounder stock. VRNT, KO pay a dividend while FORA, INFU, HCAT, CSGP do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.